{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreieivfbswqjiza3uyyddzkrfpbqsivlvflqucngwz6squwumi2ltca",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mgmwuk4524y2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifzwnomggzsrzyvuiv57h6azpq5zh6qkgwyi7lyyjjo57uchs4fde"
    },
    "mimeType": "image/jpeg",
    "size": 59239
  },
  "path": "/2026/03/09/xenon-pharmaceuticals-azetukalner-epilepsy-fos/?utm_campaign=rss",
  "publishedAt": "2026-03-09T11:00:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "biotechnology",
    "chronic diseases",
    "drug development",
    "Pharmaceuticals",
    "STAT+"
  ],
  "textContent": "Xenon Pharmaceuticals said its treatment for a common type of seizure disorder significantly reduced the frequency of those seizures compared to a placebo.",
  "title": "STAT+: Xenon Pharmaceuticals’ seizure drug shows strong efficacy in late-stage trial",
  "updatedAt": "2026-03-09T02:07:45.000Z"
}